PD-L1 expression [9], tumor mutational burden (TMB) [10], as well as microsatellite instability or DNA mismatch repair deficiency (MSI/dMMR) [11] have been approved by the Food and Drug Administration (FDA) for predicting the efficacy of treatment with ICIs in cancer patients. Here, CD274 is linked to cancer.